Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman/Hatch Reform Should Clarify Rules, Not Change System - Merck

Executive Summary

Reforms to the Waxman/Hatch patent extension program should focus on "clarification" of patent life, rather than "fundamental changes" to the generic drug approval and extension process, Merck Senior Director-Government Relations Ian Spatz told the National Institute for Health Care Management Sept. 25 in Washington, D.C.

You may also be interested in...



Patent Disputes Do Not Pay Off, Merck Says: Sweet Spot In “Bitter Medicine”

Aggressive patent defensive strategies do not pay off on Wall Street, Merck CEO Ray Gilmartin told Peter Jennings during an ABC News special, "Bitter Medicine: Pills, Profit and the Public Health," which aired May 29

Patent Disputes Do Not Pay Off, Merck Says: Sweet Spot In “Bitter Medicine”

Aggressive patent defensive strategies do not pay off on Wall Street, Merck CEO Ray Gilmartin told Peter Jennings during an ABC News special, "Bitter Medicine: Pills, Profit and the Public Health," which aired May 29

GSK Paxil, AstraZeneca Prilosec Have New "Product By Process" Patents

GlaxoSmithKline's most recent Paxil patent illustrates the latest wrinkle in patent infringement defense: "product by process" patents, attorney Robert Green (Leydig, Voit & Mayer, Chicago) told the National Association of Pharmaceutical Manufacturers bulk workshop March 20 in New York City.

Related Content

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel